Bafiertam™ (monomethyl fumarate) has been made available by Banner Life Sciences for the treatment of relapsing forms of multiple sclerosis (MS) in adults, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

Bafiertam is a novel fumarate bioequivalent alternative to its prodrug dimethyl fumarate. It was approved in April 2020 based on bioavailability studies in healthy individuals comparing oral dimethyl fumarate delayed-release capsules to Bafiertam delayed-release capsules. 

As both dimethyl fumarate and diroximel fumarate are metabolized to monomethyl fumarate, concomitant use with Bafiertam is contraindicated. Bafiertam may be initiated the day following discontinuation of either of these drugs.

Related Articles

Bafiertam is supplied as 95mg delayed-release capsules. Prior to initiating treatment, a complete blood cell count, including lymphocyte count, as well as serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained; these tests should be conducted periodically thereafter to continue to assess safety. As Bafiertam may cause flushing, administration of non-enteric coated aspirin 30 minutes before dosing may reduce the incidence and severity.

Bafiertam will be available through a network of specialty pharmacies.

For more information visit


  1. Banner Life Sciences announces Bafiertam, a novel oral fumarate treatment for relapsing forms of multiple sclerosis, is now available in the US. Accessed September 3, 2020. 
  2. Bafiertam [package insert]. High Point, NC: Banner Life Sciences LLC; 2020.